Oncternal Shares Jump After Encouraging Early Action In Soft-Tissue Sarcoma Trial With TK216

  • Oncternal Therapeutics Inc ONCT has announced updated interim clinical data from its ongoing Phase 1/2 trial evaluating TK216 in relapsed or refractory Ewing sarcoma, or soft-tissue sarcoma.
  • Data will be presented at the American Society of Clinical Oncology 2021 Annual Meeting.
  • As of the April 16 data cut-off date, two patients of 68 who achieved a complete response, remain with no evidence of disease; one for over 24 months and the other for over 14 months on study.
  • The objective response rate was 9.7% (3/31 evaluable patients), including one patient with an unconfirmed partial response.
  • 11 patients (35.5%) had stable disease, for a disease control rate of 45.2% (14/31 evaluable patients).
  • The median progression-free survival for patients was 1.9 months.
  • TK216 remained generally well tolerated with a manageable safety profile.
  • TK216 is a targeted small-molecule inhibitor of the E26 transformation-specific family of oncoproteins, including fusion proteins prevalent in Ewing sarcoma.
  • Price Action: ONCT shares are up 9.35% at $6.08 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAMoversTrading IdeasGeneralBriefssarcoma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!